68 related articles for article (PubMed ID: 35222107)
1. Trends in Pediatric Attention-Deficit Hyperactive Disorder Diagnoses and Prescription Utilization: 2016 to 2019.
Kazarov C; Peasah SK; McConnell E; Fischer KK; Good CB
J Dev Behav Pediatr; 2024 Jun; ():. PubMed ID: 38904656
[TBL] [Abstract][Full Text] [Related]
2. Trends in prescription therapy for adolescents with depression in nine major areas of China during 2017-2021.
Wang L; Zhou L; Zhu Y; Yan J; Bu N; Fei W; Wu F
Front Psychiatry; 2023; 14():1175002. PubMed ID: 37953934
[TBL] [Abstract][Full Text] [Related]
3. Off-label Prescribing Trends for ADHD Medications in Very Young Children.
Panther SG; Knotts AM; Odom-Maryon T; Daratha K; Woo T; Klein TA
J Pediatr Pharmacol Ther; 2017; 22(6):423-429. PubMed ID: 29290742
[TBL] [Abstract][Full Text] [Related]
4. Trends in Outpatient Prescribing Patterns for Ocular Topical Anti-Infectives in Six Major Areas of China, 2013-2019.
Yu Z; Zhu J; Jin J; Yu L; Han G
Antibiotics (Basel); 2021 Jul; 10(8):. PubMed ID: 34438966
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological management of attention-deficit/hyperactivity disorders (ADHD) by generalists and specialists in Germany: a secondary data analysis].
Grimmsmann T; Himmel W
Fortschr Neurol Psychiatr; 2024 Jun; ():. PubMed ID: 38866033
[TBL] [Abstract][Full Text] [Related]
6. Investigating Variations in Medicine Approvals for Attention-Deficit/Hyperactivity Disorder: A Cross-Country Document Analysis Comparing Drug Labeling.
Tanana L; Latif A; Nishtala PS; Chen TF
J Atten Disord; 2024 Feb; ():10870547231224088. PubMed ID: 38327043
[TBL] [Abstract][Full Text] [Related]
7. Trends in Prescriptions for Insomnia in a Province in China Between 2015 and 2019.
Lou G; Yu Z; Chen L; Zhou Y; Zhang L
Front Psychiatry; 2022; 13():915823. PubMed ID: 35795021
[TBL] [Abstract][Full Text] [Related]
8. Antiviral treatment in outpatients with herps zoster in six major areas of China, 2010-2019.
Yu Z; Zhao Y; Jin J; Zhu J; Yu L; Han G
Front Public Health; 2022; 10():942377. PubMed ID: 35968424
[TBL] [Abstract][Full Text] [Related]
9. Trends in use of attention deficit hyperactivity disorder medication among children and adolescents in Scandinavia in 2010-2020.
Sørensen AMS; Wesselhöeft R; Andersen JH; Reutfors J; Cesta CE; Furu K; Hartz I; Rasmussen L
Eur Child Adolesc Psychiatry; 2023 Oct; 32(10):2049-2056. PubMed ID: 35831669
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and risk factors of tigecycline-induced liver injury: A multicenter retrospective study.
Yu Z; Zhao Y; Jin J; Zhu J; Yu L; Han G
Int J Infect Dis; 2022 Jul; 120():59-64. PubMed ID: 35429639
[TBL] [Abstract][Full Text] [Related]
11. Practical clinical guidelines and pharmacological treatment for attention-deficit hyperactivity disorder in Asia.
Kawabe K; Horiuchi F; Matsumoto Y; Inoue S; Okazawa M; Hosokawa R; Nakachi K; Soga J; Ueno SI
Neuropsychopharmacol Rep; 2024 Mar; 44(1):29-33. PubMed ID: 38059346
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Methylphenidate and Atomoxetine in Medication-Naive Children with Attention-Deficit Hyperactivity Disorder in a Real-World Setting.
Zhang Y; Yin L; You C; Liu C; Dong P; Xu X; Zhang K
Drugs R D; 2024 Mar; 24(1):29-39. PubMed ID: 37982991
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and influencing factors of probiotic usage among colorectal cancer patients in China: A national database study.
Yao D; He W; Hu Y; Yuan Y; Xu H; Wang J; Dai H
PLoS One; 2023; 18(9):e0291864. PubMed ID: 37733795
[TBL] [Abstract][Full Text] [Related]
14. Patterns and Trends in Pharmacological Treatment for Outpatients with Postherpetic Neuralgia in Six Major Areas of China, 2015-2019.
Han G; Han Y; Yu L; Zhao Y; Yu Z
Healthcare (Basel); 2023 Mar; 11(5):. PubMed ID: 36900769
[TBL] [Abstract][Full Text] [Related]
15. Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China.
Li C; Guo S; Huo J; Gao Y; Yan Y; Zhao Z
Front Endocrinol (Lausanne); 2022; 13():987081. PubMed ID: 36277697
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan.
Dutta CN; Christov-Moore L; Ombao H; Douglas PK
Front Hum Neurosci; 2022; 16():938501. PubMed ID: 36226261
[TBL] [Abstract][Full Text] [Related]
17. Utilization of Drugs for Attention-Deficit Hyperactivity Disorder Among Young Patients in China, 2010-2019.
Wang Z; Wu X; Yu Z; Yu L
Front Psychiatry; 2021; 12():802489. PubMed ID: 35222107
[TBL] [Abstract][Full Text] [Related]
18. Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995-2015.
Renoux C; Shin JY; Dell'Aniello S; Fergusson E; Suissa S
Br J Clin Pharmacol; 2016 Sep; 82(3):858-68. PubMed ID: 27145886
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
